小野藥品工業在11月10日發表ONO-4538-12的報告分析，針對不合符標準治療且無法手術切除的復發性胃癌，抗PD-1抗體 Nivolumab可以增加生存期間。實驗結果的公開將於2017年的Gastrointestinal Cancers Symposium（ASCO GI)發表。因此敬請期待明年2017的 ASCO！
胃癌的用藥資訊，目前是keytruda(perbrolizumab)為加速審核的對象，目前尚未得知opdivo(nivolumab)的申請時間，但大家對於這兩種抗pd-1抗體同時使用的效果有很大的期待。
最後，各位有興趣的朋友可以參考這個網頁：Bristol-Myers Squibb
裡頭有提到關於這個臨床實驗的資訊，以及他們實施的方法。
About ONO-4538-12
ONO-4538-12 is a multicenter, double-blind, randomized, placebo-controlled, Phase 3 clinical trial conducted in Japan, Korea and Taiwan, aiming to evaluate the efficacy and safety of Opdivo in patients with unresectable advanced or recurrent gastric cancer, including gastroesophageal junction cancer, refractory to, or intolerant of, standard therapy. In this study, Opdivo 3 mg/kg or placebo was administered every two weeks until disease progression or discontinuation due to unacceptable toxicity. The primary endpoint, overall survival, was assessed for the superiority of Opdivo versus placebo.